Free Trial

Sean Laaman Analyst Performance

Analyst at Morgan Stanley

Sean Laaman is a stock analyst at Morgan Stanley in the medical sector, covering 7 publicly traded companies. Over the past year, Sean Laaman has issued 7 stock ratings, including buy, hold, and sell recommendations. While full access to Sean Laaman's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Sean Laaman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
9 Last 5 Years
Buy Recommendations
66.67% 6 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy66.7%6 ratings
Hold22.2%2 ratings
Sell11.1%1 ratings

Out of 9 total stock ratings issued by Sean Laaman at Morgan Stanley, the majority (66.7%) have been Buy recommendations, followed by 22.2% Hold and 11.1% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
85.7% of companies on NASDAQ
6 companies
NYSE
14.3% of companies on NYSE
1 company

Sean Laaman, an analyst at Morgan Stanley, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Sean Laaman of Morgan Stanley specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
71.4%
MED - DRUGS
1 company
14.3%
MED PRODUCTS
1 company
14.3%

Sean Laaman's Ratings History at Morgan Stanley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
8/18/2025Boost Price Target$60.07$90.00Overweight
Exelixis, Inc. stock logo
EXEL
Exelixis
7/29/2025Lower Price Target$37.20$46.00Overweight
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
7/3/2025Initiated Coverage$53.17$85.00Overweight
Certara, Inc. stock logo
CERT
Certara
7/3/2025Initiated Coverage$11.49$16.00Equal Weight
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
7/3/2025Initiated Coverage$103.91$190.00Overweight
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6/27/2025Boost Price Target$244.34$330.00Overweight
Alector, Inc. stock logo
ALEC
Alector
3/7/2025Reiterated Rating$1.48$1.50Underweight